Experienced in Relapsed Refractory Multiple Myeloma (RRMM)

Dr. Laura V. Stampleman

Hematology Oncology | Hematology | Oncology
5 Harris Court, Building T, Suite 201, 
Monterey, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Relapsed Refractory Multiple Myeloma (RRMM)
5 Harris Court, Building T, Suite 201, 
Monterey, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Stampleman is a Hematologist Oncology specialist and a Hematologist in Monterey, California. Dr. Stampleman is rated as an Experienced provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Bone Tumor, Multiple Myeloma, Breast Cancer, and Paget Disease of the Breast.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 1 clinical trial in the study of Relapsed Refractory Multiple Myeloma (RRMM).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

5 Harris Court, Building T, Suite 201, Monterey, CA 93940

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Study Phase: Phase 2/Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drugs: Chemotherapy, Rucaparib
Study Phase: Phase 3
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Enrollment Status: Approved_for_marketing
Publish Date: October 31, 2017
Intervention Type: Drug
View 9 Less Clinical Trials

6 Total Publications

A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 17, 2019
Similar Doctors
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Deepu Madduri
Hematology | Oncology
Elite in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Deepu Madduri
Hematology | Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (62.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Deepu Madduri is a Hematologist and an Oncologist in Stanford, California. Dr. Madduri is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Surbhi Sidana
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Surbhi Sidana
Hematology | Oncology | Hematology Oncology
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. Surbhi Sidana
Hematology | Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (62.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Surbhi Sidana is a Hematologist and an Oncologist in Stanford, California. Dr. Sidana is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). Her top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Thyroidectomy.

Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. David J. Iberri
Hematology | Hematology Oncology | Oncology
Distinguished in Relapsed Refractory Multiple Myeloma (RRMM)
Dr. David J. Iberri
Hematology | Hematology Oncology | Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (62.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Iberri is a Hematologist and a Hematologist Oncology provider in Stanford, California. Dr. Iberri is rated as a Distinguished provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Schnitzler Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stampleman's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile